Irvine, Calif., April, 2015 – ALPHAEON Corporation announced today that they
completed enrollment of two pivotal studies with their Botulinum toxin Type A
neuromodulator, EVOLUSTM, for the treatment of glabellar lines. Completing enrollment
marks a significant milestone for the Phase III development program. Recruitment for the
two U.S.-based studies began on January 2015 and was completed in March.
“We have been fortunate to partner with some of the top dermatologists and plastic
surgeons in our clinical studies.
Their research experience and clinical acumen was
evident during this important enrollment phase of our pivotal trials,” said Chris Marmo,
Ph.D., President of ALPHAEON Beauty.
ALPHAEON acquired the exclusive U.S. and certain international distribution rights to
the neuromodulator as part of its acquisition of Evolus Inc. in October of 2013.
About ALPHAEON Corporation
ALPHAEON Corporation is the first social commerce company transforming self-pay
healthcare by bringing to market highly innovative products and services to promote
consumer wellness, beauty and performance.
The company works in partnership with
board certified physicians ensuring access to leading advancements in lifestyle
healthcare. For more information, please visit www.alphaeon.com.
PRESS CONTACT:
Jenna Mons, Senior Vice President of Marketing and Communications
Tel: 949-284-4523
Email: press@alphaeon.com
ALPHAEON® is a registered trademark of Alphaeon Corporation
EvolusTM is a trademark of ALPHAEON Corporation
No comments:
Post a Comment